



Neuroprotective Strategies in Neurodegenerative Diseases Group

Publications: 8

Q1: 4



RESEARCH ACTIVITY

■ Doctoral theses

Master Theses

Jiménez Villegas J. Role of NRF2 in C9ORF72 and RNA-related ALS pathology[dissertation]. Madrid: UAM: 2021(18/06/2022).

Directors: Rojo Sanchís AI, Cuadrado Pastor A.

Cañizares Moscato L. Preclinical development of P10, a novel small molecule NRF2 activator[dissertation]. Madrid: UAM: 2021(04/07/2022).

Directors: Cuadrado Pastor A, García Yagüe AJ.

Lucas Castro E. Role of the transcription factor NRF2 in the regulation of the integrity and function of the blood-brain barrier[dissertation]. Madrid: UAM: 2021(28/06/2022).

Directors: Cuadrado Pastor A, Pajares M

Final Degree Theses

Fariñas García S. Vesículas extracelulares en el interactoma hepático en la enfermedad de hígado graso no

alcohólico[dissertation]. Madrid: UCM: 2021(07/06/2022).

Director: Martínez Valverde A.

Martín Ortiz B. Mecanismos moleculares asociados al desarrollo de la enfermedad de hígado graso no alcohólico[dissertation]. Madrid: UCM: 2021(07/06/2022).

Director: Martínez Valverde A.

■ Publications

• Duarte P, Cuadrado A, Leon R. Monoamine oxidase inhibitors: From classic to new clinical approaches. *Handb Exp Pharmacol.* 2021; 264:

229-59. Article. Not Indexed

- García-Yagüe AJ, Lastres-Becker I, Stefanis L, Vassilatis DK, Cuadrado A. alpha-Synuclein Induces the GSK-3-Mediated Phosphorylation and Degradation of NURR1 and Loss of Dopaminergic Hallmarks. *Mol Neurobiol.* 2021; 58(12): 6697-711. Article. IF: 5.682; Q1
- Jiménez-Villegas J, Ferraiuolo L, Mead RJ, Shaw PJ, Cuadrado A, Rojo AI. NRF2 as a therapeutic opportunity to impact in the molecular roadmap of ALS. *Free Radical Bio Med.* 2021; 173: 125-41. Article. IF: 8.101; Q1
- Kliinsky DJ, Abdel-Aziz AK, Abdelfatah S, Abdellatif M, Abdoli A, Abel S, Abeliovich H, Abildgaard MH, Abudu YP, (et al) Yakhine-Diop SMS. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). *Autophagy.* 2021; 17(1): 1-382. Review.

IF: 13,391; Q1

- Lastra D, Fernández-Ginés R, Manda G, Cuadrado A. Perspectives on the clinical development of NRF2-targeting drugs. *Handb Exp Pharmacol.* 2021; 264: 93-141. Article. Not Indexed
- Milanese E, Cucos Catalina A, Matías-Guiu JA, Pinol-Ripoll G, Manda G, Dobre M, Cuadrado A. Reduced blood RGS2 expression in mild cognitive impairment patients. *Front Aging Neurosci.* 2021; 13: 738244. Article. IF: 5.702; Q1
- Milanese E, Dobre M, Cucos CA, Rojo AI, Jiménez-Villegas J, Capetillo-Zarate E, Matute C, Pinol-Ripoll G, Manda G, Cuadrado A. Whole blood expression pattern of inflammation and redox genes in mild Alzheimer's disease. *J Inflamm Res.* 2021; 14: 6085-102. Article. IF: 4.631; Q3
- Milanese E, Manda G, Dobre M, Codrici E, Neagoe IV, Popescu BO, Bajenaru OA, Spuru L, Tudose C, Prada GI, Davidescu EI, Pinol-Ripoll G, Cuadrado A. Distinctive under-expression profile of inflammatory and redox genes in the blood of elderly patients with cardiovascular disease. *J Inflamm Res.* 2021; 14: 429-42. Article. IF: 4,631; Q3

■ Research projects

Cuadrado A; Lastres-Becker I. Papel de NRF2 en la función y el destino del cerebro con Alzheimer (SAF2016-76520-R). MICINN. 2017-2020.

Managment centre: UAM

Cuadrado Pastor A, Rojo Sanchís AI. El factor de transcripción NRF2 en la patofisiología de la enfermedad de Alzheimer (1004020167). MICINN. 2020-2023.

Managment centre: UAM

Cuadrado Pastor A. Desarrollo de fármacos activadores de NRF2 para terapias innovadoras de la enfermedad de Alzheimer - GT2 (2018/00050/001). CAM. 2018-2022.

Managment centre: UAM

Cuadrado Pastor A. Investigación traslacional sobre la regulación farmacológica NRF2 en enfermedades no transmisibles (10.2J.01.03). MICINN. 2020-2022.

Managment centre: UAM

Martínez Valverde A. Extending the knowledge of the cellular and molecular mediators in the progression and treatment of non-alcoholic fatty liver disease linked to obesity (FATLiV). (RTI2018-094052-B-I00). MICINN. 2019-2022.

Managment centre: CISC

Martínez Valverde A. Extracelular vesicles: new insights into their role in liver-pancreas interactome in T2D. European Association for the Study of Diabetes. 2021-2023.

Managment centre: CIBER

Martínez Valverde A. Identification of metabolic biomarkers for chronic diseases and treatments/Identificación de biomarcadores metabólicos para enfermedades crónicas y sus tratamientos (EIN2020-112263). MICINN. 2021-2022.

Managment centre: CISC

Martínez Valverde A. Mecanismos moleculares y comunicación intertisular en la resistencia a la insulina (B2017/BMD-3684 MOIR2-CM). CAM. 2018-2022.

Managment centre: CISC

Martínez Valverde A. New messengers in the interactome of hepatic and extra-hepatic cells in non-alcoholic fatty liver disease with diagnostic value. Fundación Ramón Areces. 2019-2022.

Managment centre: CISC

Martínez Valverde A. Training European Network: Metabolic Dysfunctions associated with Pharmacological Treatment of Schizophrenia (ITN-TREATMENT Grant

Agreement 721236.). EU. 2017-2021.

Managment centre: CISC

Rojo Sanchís AI. NRF2: Biomarcador y evaluación como diana terapéutica para la esclerosis lateral amiotrófica (10.04.02.0149). Fundación Tatiana. 2019-2021.

Managment centre: UAM

■ Cibers and Retics

Cuadrado Pastor A. Networked Biomedical Research Center for Neurodegenerative Diseases. (CB06/05/0010). ISCIII. (2022).

Managment centre: UAM

Martínez Valverde AM. Networked Biomedical Research Center for Diabetes and Associated Metabolic Diseases. (CB07/08/0033). ISCIII. (2022). IIBm Alberto Sols-UAM, CSIC.

Managment centre: IIBm Alberto Sols-UAM, CSIC

■ Patents and trademarks

Cuadrado Pastor A, Innamorato NG, inventors: CSIC, UAM. Use of sulforaphane as supplementary therapy for early-stage neurodegenerative disease. P201231693; 2012 November 06.

León Martínez R, Egea Maíquez J, Buendía Abaitua I, Parada Pérez E, Navarro González de Mesa E, inventors; Fundación

para la Investigación Biomédica del Hospital Universitario de La Princesa, UAM, CSIC, DNS NEUROSCIENCE S.A., assignees. Use of 3-(2-isothiocyanatoethyl)-5-methoxy-1H-indole for the treatment of neurodegenerative diseases. P201300667; 2013 July 17.

León Martínez R, Buendía Abaitua I, Navarro González de Mesa E, Michalska P, Gameiro Ros I, López Vivo A, Egea Maíquez J, García López M, García García A, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa, UAM, DNS NEUROSCIENCE S.A., assignees. Compounds derived from 3-alkylamine-1H-indolyl acrylate and its use for the treatment of neurodegenerative diseases. P201400810, PCT/ES2015/000139, CA2964309; 2014 October 15.

